Aflibercept for Age-Related Macular Degeneration: A Game-Changer or Quiet Addition?
Purpose To describe the pharmacokinetics, preclinical studies, and clinical trials of the newly approved anti–vascular endothelial growth factor (VEGF) drug aflibercept (Eylea (VEGF Trap-Eye); Regeneron; and Bayer). Design Review with…